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ABSTRACT
Disease mongering starts at the top of recent accusations being hurled at psychiatry. It is used to 
refer to the attempts by pharmaceutical companies or others who have similar interests, to enlarge 
the market for a treatment by convincing people that they are sick and need medical intervention. 
This paper critically analyses the ‘for’ and ‘against’ arguments of disease mongering in psychiatric 
disorders, both new and old, such as Bipolar disorders, attention deﬁ cit hyperactivity disorder, 
Restless legs syndrome, Premenstrual dysphoric disorder, female sexual dysfunction, social phobia, 
metabolic syndrome and road rage disorder
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INTRODUCTION
If I shop too much, I suffer from compulsive shopping 
disorder.
If I am shy, I have social phobia. 
If I shake my legs while I think, I have restless legs 
syndrome.
If I am driving too fast to get somewhere, I probably 
have Road Rage Disorder. 
If I am losing hair, I am mostly stressed out and I need 
anxiolytics.
Psychiatry today stands on the verge of being declared 
the “discovery of the decade”, with rapid advancements 
being made each day in the understanding of the human 
brain and consequently, psychiatric disorders. One would 
only have to take a look at the increasing acceptance 
by both our professional brethren from other disciplines 
as well as the general public to know that this is not 
an exaggeration. Yet, like all good things come hand-
in-glove with a few bad ones, psychiatry has also been 
recently plagued with several controversies, such as 
ethics of clinical trials, the “discovery” of antipsychotic 
induced metabolic syndrome and of accusations of 
cosmetic psychopharmacology. Disease mongering 
starts at the top of the queue here. 
CONCEPT
The term “disease mongering” was ﬁ rst described by 
Lynn Payer in the 1990s  and has been subsequently 
modiﬁ ed to refer to the attempts by pharmaceutical 
companies or others who have similar interests, to 
enlarge the market for a treatment by convincing 
people that they are sick and need medical intervention. 
What this involves is the creation of so-called new 
diseases, and then rapid research into it to disseminate 
information. The problem with these ‘new diseases’ is 
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that the diagnosis of the symptoms could span a broad 
spectrum of severityfrom nonspeciﬁ c symptoms and 
everyday experiences, to profound suffering. 
One may argue that knowledge about any disease is 
good as it helps keep the general public in good health 
by improving awareness and enabling them to take pre-
emptive action. Unfortunately, it does another thing 
too- it also helps increase the size of the market by 
reducing the boundaries between health and sickness 
so that normal experiences get labeled as pathological, 
and by expands the deﬁ nition of disease to include 
milder and even pre-symptomatic forms. This can be 
easily discernible in the patterns of spending of the 
pharmaceutical industry, which spends more money 
on marketing and advertising than on research and 
development.
However, there is another side to this story too. The 
critics of this concept argue that marketing practices in 
the pharmaceutical industry are similar to those in other 
industries, all of which emphasise increasing markets 
for and maximising use of their products. They also say 
that they are only providing the public with information 
about treatment options and that actual prescription is 
a matter between patient and doctor. They therefore 
complain that is unfair to single them out and label them 
as “bad”. Sometimes, critics have even accused the 
proponents of disease mongering as being extensions of 
the Scientology based organizations and antipsychiatry 
movement  in an attempt to discredit psychiatry, 
neurobiological disorders, and the medications used for 
treatment.
DISEASE MONGERING IN PSYCHIATRY
Initially, pharmaceutical companies targeted general 
consumers with “lifestyle drugs” for cosmetic and sexual 
enhancements. This has now been broadened to include 
other areas of medicine, including psychiatry. Marketing 
campaigns of pharmaceutical companies, which initially 
focused on cosmetic and sexual enhancements, have 
recently crossed-over to selling psychotropic drugs. 
Since most of these drugs have a very wide range of 
active properties, the interpretation of their ‘effects’ is 
also used with a great degree of “wideness” by the 
marketer. For example, one class of antidepressants, 
the speciﬁ c serotonin reuptake inhibitors (SSRIs), is 
marketed for eight distinct psychiatric conditions, 
ranging from social anxiety disorder to obsessive-
compulsive disorder to a non-existent (at least in 
textbooks) premenstrual dysphoric disorder. 
One can gauge the seriousness of this issue by the 
content of a recent New York Times article: “For a sizable 
group of people in their 20’s and 30’s, deciding on 
their own what drugs to take—in particular, stimulants, 
antidepressants and other psychiatric medications—is 
becoming the norm. Conﬁ dent of their abilities and often 
skeptical of psychiatrist’s expertise, they choose to rely 
on their own research and each other’s experience in 
treating problems like depression. A medical degree, in 
their view, is useful but not essential”. The emergence 
of this potentially dangerous situation demonstrates 
an increasing expansion of the drug industry into an 
already accepted mode of thought—that “every minor 
mood ﬂ uctuation,” as the article reported, can and 
should be remedied.
The broad inﬂ uence of the pharmaceutical industry 
does not just stop there. This inﬂ uence now extends 
to wide domains such as initiating clinical studies or 
inﬂ uencing outcomes in research publications, lobbying 
with governments and regulatory agencies, getting 
involved in educative programs, advertising and point-
of-use promotion, drug distribution among pharmacies 
and interfering in patients’ medicative practices on 
the pretext of ensuring compliance. Pharmaceutical 
companies are now engaged in direct advertisements 
to customers whereby they induce patients to become 
equal partners with industry and reap huge proﬁ ts.
COMMENT
The negative consequences of disease mongering are 
only to be seen to be believed. Many of life’s normal 
processes like birth, ageing, sexuality, unhappiness 
and death have been medicalised. Since simply labeling 
people with disease can have negative consequences, 
we are now confronted with a situation of every man/
woman popping a pill everyday to stay away from illness. 
It’s been called the “medicalisation of our society—the 
pill for every ill.” Yet, one fails to understand if this 
‘panic reaction’ is indeed true or a creation of conspiracy 
theorists. A critical dissection of the ‘for’ and ‘against’ 
arguments is therefore essential.
DISEASE MONGERING IN BIPOLAR DISORDERS
Bipolar disorders are one of the most investigated 
disorders in psychiatry, primarily since there is both a 
cure as well as prevention for it. Naturally, they have also 
attracted the most attention by proponents of disease-
mongering. An increasing number of epidemiological 
surveys have noted an increasing prevalence of bipolar 
disorders. Whether this reﬂ ects an unearthing of hitherto 
hidden disease or an attempt to ‘sell’ bipolar disorders 
is yet not clear. The chief criticism in these surveys 
has been the absence of clearly deﬁ ned criterion for 
disability arising due to the illness and the manufacturing 
of other bipolar types such as bipolar 1, 2, 2.5, 3, 3.5, 
4, 5, and 6 popularly called as the ‘bipolar spectrum 
disorders’. Such an attempt to dilute the concept of 
bipolar disorders may mean that actual patients may 
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suffer and put a question mark on the validity of the 
diagnosis, although it is entirely implausible that mania 
and melancholia were also manufactured by Esquirol 
and Kraepelin.
A similar argument has been made for treatments of 
bipolar disorders. Statements such as “bipolar disorder 
is often a lifelong illness needing lifelong treatment; 
symptoms come and go, but the illness stays; people 
feel better because the medication is working; almost 
everyone who stops taking the medication will get 
ill again and the more episodes you have, the more 
difﬁ cult they are to treat” and that “medicines are 
crucially important in the treatment of bipolar disorders” 
only serve to perpetuate the accusation of disease-
mongering. Similarly, claiming that ‘studies over the 
past twenty years have shown beyond the shadow of 
doubt that people who receive the appropriate drugs 
are better off in the long term than those who receive 
no medicine’ are a little hard to digest. Every clinician 
involved in the treatment of psychiatric illnesses knows 
that these are difﬁ cult statements to make, especially 
when the risk-beneﬁ t ration of psychotropic drugs is 
not that good. There is also evidence to show that 
psychotropic medications have done little to change the 
prevalence of admissions in bipolar disorders and that 
there is a higher rate of suicide in bipolar patients on 
psychotropic medications than on placebo.
Many websites are being added every day to “educate” 
patients on bipolar disorders. A simple search on 
bipolar disorders on Google brings up http://www.
bipolarawareness.com/, http://www.bipolarhelpcenter.
com/, and http://www.bipolar.about.com/.Websites by 
health professionals dealing with bipolar illness are few 
and far in between. This attempt to ‘educate’ patients 
would certainly raise a few eyebrows, since the top 
websites are sponsored by major pharmaceutical 
companies. However, it is also a fact that patient 
education always does not amount to disease 
mongering. For example, http://www.psycheducation.
org is a website that gives information about bipolar 
disorders, earning it the Mofﬁc Award for Ethical 
Practice in Community Psychiatry.  One would have to 
conclude that, although not all research is ‘inﬂ uenced’, 
it is entirely possible that over-diagnosis is carried out 
often inﬂ uenced by the pharmaceutical industry.
Currently, there is serious criticism of the trend of 
diagnosing bipolar disorders in children. Since, there 
are no established criteria to do so, it is difﬁ cult to 
believe the increasing prevalence from 1% to 32%. 
Today, even everyday behavioral difﬁculties are now 
better seen in terms of a disorder, and children as 
young as two years are being diagnosed with bipolar 
disorder.The fashion to diagnose bipolar disorders in 
children has now reached feverish proportions with 
even Time magazine, in August 2002, featuring nine-
year-old Ian Palmer and a cover title called ‘Young and 
Bipolar’. Although pediatric bipolar disorder is a reality, 
serious research into this debilitating condition has been 
unfortunately hampered by statements of some experts 
who have even gone to the extent of saying that that 
the ﬁ rst signs of bipolar disorder may be patterns of 
over-activity in-utero.
COMMENT
Although most of the criticism of bipolar disorders 
is unwarranted, there is a need to exercise serious 
restraint among researchers. There have been instances 
when articles have been “ghostwritten” for well-
respected medical researchers in prestigious journals, 
and even where some of them have articles authored by 
(prominent) people who stand to directly beneﬁ t from 
promoting certain treatment regimens in the articles. 
When these same articles are thrust in our (doctors’) 
faces by visiting marketing representatives, it makes it 
difﬁ cult to reject such claims. It makes the situation so 
complex that we are no longer aware of what research 
to trust and what not to. We must understand that our 
basic emotions-love, hate, happiness, sadness, anger 
etc. cannot be medicalised. The other extreme that 
has been depicted in the movie “Equilibrium,” where 
all mood ﬂ uctuations are controlled by pills, is too 
horrifying to be even imagined.
DISEASE MONGERING IN ADHD
Attention deﬁ cit hyperactivity disorder is a serious 
problem afﬂ icting 5.29% of children and adolescents 
around the world with persistence of symptoms into 
adulthood noted to be in the range of 4-66%. Although 
there are well deﬁ ned diagnostic criteria laid down 
by both DSM IV and ICD 10, yet the danger of over-
diagnosis is constantly present and currently, this runs a 
close second to bipolar disorders as the most diagnosed 
condition.
The DSM-IV diagnostic criterion permits teachers to 
play an important role in diagnosis through the use of 
specialised assessment instruments such as the Conners 
Teacher’s Rating Scale. In a study of 491 physicians in 
Washington, D. C., almost half of the diagnoses of ADHD 
in their patients had been suggested ﬁ rst by teachers, 
an argument advance by critics that teachers are now 
“disease-spotters,” who engage in disease-spotting 
[38]. Websites funded by pharmaceutical companies 
are big sources of information which “educates” 
teachers on the diagnosis and management of ADHD. 
Educational programs are also held to publicize ADHD 
through funding from companies. And advertisements 
for atmoxetine, the ﬁ rst approved medication for adult 
ADHD, which suggests that consumers get checked 
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out by their physician, so that “they stay focused and 
can get things done at work and at home,” certainly 
don’t help.
Similar criticism has been leveled at adult ADHD. The 
biggest criticism has been that ADHD is just a set of 
normal behavioral variations, with no neurological basis 
for the same. The above author has repeatedly said 
that the concept of ADHD is a fraud with psychiatry 
making “Patients” of normal people and has testiﬁ ed 
widely about the absence of proof of causation of 
ADHD. Unfortunately, there is also a serious dearth 
of epidemiological research on ADHD. Clinicians 
treating ADHD also know that this is a real condition 
that impairs and disables people, and people suffering 
from this condition are thankful they were “diagnosed, 
treated and had their attention span restored to almost 
normal.”.
COMMENT
ADHD is a serious condition that impairs and disables 
severely if untreated. To say that this is a complete 
ﬁ gment of imagination  is pushing it too far. Since it 
is a condition that has only recently been recognized, 
it is but natural that there will be both false and true 
studies. Eventually, it will be as recognized and accepted 
as AIDS, a condition which drew similar accusations 
decades ago when it was ﬁ rst discovered. Until such a 
time, it is imperative that people with this disorder are 
not over-treated with psychostimulants and that they 
are subjected to psychological interventions too. 
DISEASE MONGERING IN PREMENSTRUAL 
DYSPHORIC DYSFUNCTION (PMDD)
The biggest support of the argument that new diseases 
are being created everyday comes from the diagnosis 
of PMDD or Premenstrual Dysphoric disorder which 
does not exist in more than half the world, was earlier 
considered as part of normal menstrual cycle and is not 
recognized by the ICD 10.Yet the US FDA has already 
approved even a treatment regimen for the same 
effectively accepting the existence of the condition. One 
wonders what the hurry was in approving treatment for 
a condition that ofﬁ cially does not even ‘exist’.
It is a fascinating story that details the discovery of the 
disease. Word has is that the owners of a certain brand 
of ﬂ uoxetine were about to lose their patent. They then 
funded a meeting of researchers and FDA ofﬁ cials where 
PMDD was ‘ofﬁ cially’ born and Fluoxetine (in another 
brand name) was approved as treatment of choice. By 
then the makers had redesigned and repackaged the 
same drug and sold it under a different brand name, 
“the smart drug for smart women” [40]. Similarly 
Australia, following the lead of FDA has also approved 
the use of SSRIs for treatment of PMDD but does not 
cover the costs of treatment under medical insurance. 
However, the biggest setback for PMDD promoters and 
a shot in the arm for activists of disease mongering 
came from the refusal of the European Medicines 
Evaluation Agency, citing concerns that women “with 
less severe pre-menstrual symptoms might erroneously 
receive a diagnosis of PMDD resulting in widespread 
inappropriate short- and long-term use of ﬂ uoxetine”. 
Lilly has stopped marketing the drug in Europe. The 
debate remains wide open between supporters and 
those against the validity of the diagnosis of PMDD.
COMMENT
PMDD may be a disorder that is fully deﬁ ned in the 
future, or it may just be a fad like what Chronic Fatigue 
syndrome has often been accused of. Since the 
boundaries of this disorder and hence the prevalence is 
not deﬁ ned, treatments for this should wait until they 
undergo rigorous evaluation.
DISEASE MONGERING IN RESTLESS LEGS 
SYNDROME
The diagnosis of restless legs syndrome requires the 
presence of the following four criteria according to a 
recent report:
An urge to move the legs due to an unpleasant feeling 
in the legs. 
Onset or worsening of symptoms when at rest or not 
moving around frequently. 
Partial or complete relief by movement (e.g., walking) 
for as long as the movement continues. 
Symptoms that occur primarily at night and that can 
interfere with sleep or rest.
After “awareness” of so-called criteria, one major 
pharmaceutical company then promoted the illness, 
beginning with press releases about presentations 
at the American Academy of Neurology meeting 
describing the early trial results of using ropinirole (a 
drug previously approved for Parkinson disease) for 
the treatment of restless legs [43]. Two months later, 
the same company issued a new press release entitled 
“New survey reveals common yet under recognized 
disorder—restless legs syndrome—is keeping Americans 
awake at night” about an internally funded and, at the 
time, unpublished study. In 2005, the US Food and 
Drug Administration (FDA) approved ropinirole for the 
treatment of restless legs syndrome which became the 
ﬁ rst drug approved speciﬁ cally for this indication. Since 
then, the campaign to promote restless legs syndrome 
into the consciousness of doctors and consumers alike” 
has reached disturbing extents. It has exaggerated 
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the prevalence of disease and the need for treatment, 
and failed to consider the problems of overdiagnosis. 
Increasing number of articles and research papers 
published on this topic have only fuelled the epidemic.
Comment: Like PMDD, restless legs syndrome is a 
disorder that has neither body nor soul. Since there 
is no empirical scientiﬁ c evidence available, which is 
agreeable to all professionals across the board, doctors 
should tread carefully and consider other possibilities 
before coming to this diagnosis. 
OTHER PSYCHIATRIC DISORDERS:
Dementia:  The use of various drugs to treat dementia, 
such as anti-cholinesterase inhibitors, have been recently 
criticized as lacking clinical evidence, since most trials 
of donepezil, rivastigmine and galantamine have been 
limited by underpowered studies, poor methodological 
quality and using invalidated scales or instruments to 
measure improvement. Most meta-analyses and reviews 
of treatment beneﬁ ts of cholinesterase inhibitors in both 
Alzheimer’s, Parkinson’s and vascular dementia have 
found low treatment effect, minimal beneﬁ ts, biased 
reporting and mixed and confusing results. This has 
prompted United Kingdom’s National Institute for Health 
and Clinical Excellence (NICE) guidelines to state that 
clinical outcome of use of cholinesterase inhibitors is 
limited and largely inconclusive and not recommending 
its use. However, in a later change, the updated 
guidelines state that they may be used for moderate 
types of Alzheimer’s disease. An integrated approach 
involving both psychosocial and pharmacological 
strategies individualized for each patient is essential 
as even a moderate improvement in a patient with 
dementia may appear ground-breaking for both patient 
and carer.
Social Phobia: Shyness has a new name-social phobia. 
Although this disorder exists in reality, the methods 
by which this diagnosis is being pushed and promoted 
is deplorable. In Australia, a certain pharmaceutical 
company claimed that one million Australians suffered 
from social phobia. The condition was described as “soul 
destroying” and antidepressants were recommended for 
treatment. However, such a claim may be part of a wider 
push to change the common perception of shyness, 
from a personal difﬁ culty to a psychiatric disorder. 
Even Pharmaceutical Marketing’s practical guide was 
led to come out and declare that the promotion of 
social phobia was a positive example of drug marketers 
attempting to shape medical and public opinion about 
a disease. Once again, lest the real patients be missed 
in all this promotion, one needs to be on guard against 
such blatant use of marketing.
Female sexual dysfunction: Female sexual dysfunction 
(FSD) was almost created overnight when 
pharmaceutical companies, sponsored a May 1997 
Cape Cod conference, “Sexual Function Assessment in 
Clinical Trials,” bringing together papers and discussion 
which were published in a special supplement to the 
International Journal of Impotence Research. After 
that, there was no stopping the rapid dissemination of 
information on a disease that did not exist- television 
programs such as “Oprah”; Web sites, and books and 
in innumerable women’s magazines. Viagra and then 
a testosterone patch were promoted as treating FSD. 
Efforts are now on to include this in the ofﬁ cial directory 
of diseases ICD and DSM. Whether the condition exists 
in reality or is a ﬁ gment of a marketer’s imagination 
remains to be seen. 
Metabolic syndrome: Metabolic syndrome has 
become the new rage in psychiatry, especially in 
psychopharmacology. However, this concept has not 
been viewed as being promoted by drug manufacturers 
as they only stand to lose with what is being rapidly 
seen as a detrimental effect of second generation 
antipsychotics. Research papers on the topic are being 
published nearly every day including that of this author. 
However, questions have been raised whether: 1) is it 
indeed a syndrome, particularly as the precise cause 
is unknown, 2) does it serve a useful purpose, and 3) 
is it labelling (and medicalising) people unnecessarily? 
Additionally, an editorial has suggested that recognition 
of the metabolic syndrome is being largely driven 
by industry to create new markets. Even as serious 
researchers, we need to consider the likelihood of a 
market-driven campaign before jumping in favor of the 
diagnosis. Ultimately, all we are looking out for is the 
patient’s interest.
Road rage and compulsive shopping have been added to 
the ever growing list of doubtful diagnoses. Promoted 
by both media and psychiatrists, these have invited 
serious concerns whether psychiatry is turning every 
aspect of human behavior into a disease. Such has been 
the ridiculousness of disease mongering that when BMJ 
printed a “news” item that appeared in its April Fool’s 
Day edition 2006, titled “Scientists ﬁ nd new disease: 
motivational deﬁ ciency disorder”, people actually 
thought it was true and started writing in to say they 
suffered from it.
FINAL CRITIQUE:SUMMARY
As doctors, we are often so pressed for time that 
we take research at face value as do we claims by 
pharmaceutical representatives. One is reminded of 
Aristotle, who so rightly observed that “truth could 
inﬂ uence only half a score of men in a century, while 
falsehood and mystery would drag millions by the nose.” 
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The issue is even more serious in countries like India 
where pharmaceutical companies offer various gifts to 
lure and change the prescribing habits of physicians. 
Drug companies have been known to have leading 
researchers as consultants, sponsor annual scientiﬁ c 
meetings, and fund continuing medical education (CME) 
programmes. Medical representatives are allowed free, 
unrestricted access to doctors and medical conferences 
are now strongly dominated by the industry. Psychiatry, 
although not the top priority for most pharmaceutical 
companies, has started to be “recognized” as a potential 
ﬁ eld of play. Even though we may argue that there may 
be no way out of this, we as doctors can do our bit. 
Doctors should develop the capacity for critical analysis 
of research reports and should avoid being misled by 
biased presentation and interpretation of data. Journal 
articles, although highly valuable sources of information 
should not be depended on as the only source. Such 
critical appraisal skills should be made part of the 
undergraduate medical course along with prescribing 
skills. The economics of each drug should be acquired 
and remembered while prescribing. Doctors should be 
more careful while attending CME programmes and 
conferences which are sponsored by the industry. 
Disease mongering is neither pure black nor white. 
Unfortunately, the concept of disease is also a ‘grey 
zone’, with inadequate deﬁ nition of boundaries. There 
will always be “normal” people who will want treatment 
and “sick” people who will refuse it. A holistic approach 
to the patient and patient care is therefore required 
while deciding treatment strategies. 
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